Skip to main
DRIO

DarioHealth (DRIO) Stock Forecast & Price Target

DarioHealth (DRIO) Analyst Ratings

Based on 3 analyst ratings
Buy
Strong Buy 67%
Buy 0%
Hold 33%
Sell 0%
Strong Sell 0%

Bulls say

DarioHealth is well-positioned for success in the growing digital health market, with a unique vertically integrated platform and strong focus on customer engagement and clinical outcomes. Despite recent challenges in their B2B2C and strategic partnerships channels, the company has improved its pipeline and commercial progress, leading to optimism for future revenue growth and potential EBITDA breakeven by 2026/2027. However, risks associated with the HCIT space and potential challenges in achieving customer retention and capturing sufficient lives may impact the company's future success.

Bears say

DarioHealth is a virtual chronic care company that provides personalized digital and human coaching on chronic conditions and owns a complete chain of value in chronic care management. However, there are potential risks associated with the healthcare IT (HCIT) space, including constrained hospital budgets and customer losses due to facility consolidation, which could hinder DarioHealth's growth potential. Additionally, the company's focus on B2B2C solutions and the need for continuous cash flow may lead to dilutive capital raises, limiting its cash runway.

DarioHealth (DRIO) has been analyzed by 3 analysts, with a consensus rating of Buy. 67% of analysts recommend a Strong Buy, 0% recommend Buy, 33% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of DarioHealth and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About DarioHealth (DRIO) Forecast

Analysts have given DarioHealth (DRIO) a Buy based on their latest research and market trends.

According to 3 analysts, DarioHealth (DRIO) has a Buy consensus rating as of Sep 28, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $10, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $10, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

DarioHealth (DRIO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.